|
User Fee Section on Drug Shortages Will Overburden FDA, Expert Says
BOSTON — Language in the finalized FDA user fee bill requiring early notification on manufacturing changes that could create drug shortages is so vague that drugmakers will flood the agency with reports, causing more harm than good, a former FDA associate commissioner says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives